David Dantzker - Nov 14, 2022 Form 4 Insider Report for SURMODICS INC (SRDX)

Role
Director
Signature
/s/ John Manders, on behalf of David R. Dantzker
Stock symbol
SRDX
Transactions as of
Nov 14, 2022
Transactions value $
-$3,401
Form type
4
Date filed
11/15/2022, 03:28 PM
Previous filing
Feb 14, 2022
Next filing
Feb 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRDX Common Stock Options Exercise $88.1K +4.37K +13.4% $20.18 37K Nov 14, 2022 Direct
transaction SRDX Common Stock Sale -$91.5K -2.77K -7.5% $33.00 34.2K Nov 14, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRDX Stock Option (right to buy) Options Exercise $0 -4.37K -100% $0.00* 0 Nov 14, 2022 Common Stock 4.37K $20.18 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the weighted average price of 2,773 shares of common stock of Surmodics, Inc. sold by the reporting person in multiple transactions on November 14, 2022 with sale prices ranging from $32.9021 to $33.18 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F2 The amount beneficially owned includes 11,985 restricted stock units (RSUs) that vest on service-based vesting dates and 15,415 DSUs that are vested upon issuance, each of which will be settled in shares of the issuer's common stock on a 1 for 1 basis when the reporting person's service as a director ends.
F3 Fully vested.